Business
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Decoy Therapeutics Inc. (Nasdaq: DCOY), a clinical-stage biotechnology company pioneering a new category of antivirals, today announced the appointment of Brad L. Pentelute, Ph.D., Professor of Chemistry at the Massachusetts Institute of Technology, as Chair of its Scientific Advisory Board (SAB). Dr. Pentelute is an original co-founder of Decoy and has served as a Technology Advisor since the company's inception. He is widely recognized for his foundational contributions to peptide synthesis an
About this update from Decoy Therapeutics Inc.
[{"type":"text","content":"Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development","length":127,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK and CAMBRIDGE, Mass., May 26, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a clinical-stage biotechnology company pioneering a new category of antivirals, today announced the appointment of Brad L. Pentelute, Ph.D., Professor of Chemistry at the Massachusetts Institute of Technology, as Chair of its Scientific Advisory Board (SAB). Dr. Pentelute is an original co-founder of Decoy and has served as a Technology Advisor since the company's inception. He is widely recognized for his foundational contributions to peptide synthesis and protein engineering.","length":586,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":104,"url":"https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YyEL5SG8p3qov4E54_d53A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4Mw--/https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a","width":400,"height":104},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/AwUheBev7B0Yn4Z7RsmGxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE2Ng--/https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a","width":400,"height":104}},"href":"https://mma.prnewswire.com/media/2859955/Decoy_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"As Chair of the SAB, Dr. Pentelute will help guide the scientific direction of Decoy's IMP3ACT™ platform and its expanding pipeline of Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, enabling a single drug to work across multiple viral threats. IMP3ACT, Decoy's proprietary peptide conjugate platform, integrates AI-enabled design with rapid synthesis to advance candidates faster than traditional approaches.","length":483,"tagName":"p"},{"type":"text","content":""Brad has been part of Decoy's science from the start. He is one of the most respected voices in pe...